

DOCKET NO.: ACTE-0002

TEx 1615  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

**Mezher Hussein Ali, et al.**

**Confirmation No.: 3691**

**Application No.: 10/522,208**

**Group Art Unit: 1615**

**Filing Date: October 27, 2005**

**Examiner: Not Yet Assigned**

**For: PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF  
GLYCOSYLCERAMIDE SYNTHASE**

DATE OF DEPOSIT: *May 17, 2006*

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE UNITED STATES PATENT AND  
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,  
VA 22313-1450.

*Elizabeth A. McLoud*

TYPED NAME Elizabeth A. McLoud

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.


- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
  - Certification in Accordance with § 1.97(e) is attached; or
  - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of reference numbers 1 - 45 listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
- Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: *5/16/06*



David A. Cherry  
Registration No. 35,099

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. ACTE-0002	Application No. 10/522,208
		Applicant Mezher Hussein Ali, et al.	
		Filing Date October 27, 2005	Group 1615
		Confirmation No. 3691	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>1</b>	Abe, A., et al., "Reduction of globotriaosylceramide in fabry disease mice by substrate deprivation," <i>J. Clin. Invest.</i> , <b>2000</b> , <i>105</i> (11), 1563-1571	
	<b>2</b>	Alessandri, G., et al., "Angiogenic and angiostatic microenvironment in tumors," <i>Acta Oncol.</i> , <b>1997</b> , <i>36</i> , 383-387	
	<b>3</b>	Alter, M., "GM1 ganglioside for acute ischemic stroke – trial design issues," <i>Ann. NY Acad. Sci.</i> , <b>1998</b> , <i>845</i> , 391-401	
	<b>4</b>	Bramer, S.L., et al., "Biologic activity of 5'-deoxy-5-fluorouridine by rectal administration," <i>Pharmaceutical Res.</i> , <b>1989</b> , <i>6</i> (4), 318-322	
	<b>5</b>	Chatterjee, S., et al., "Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease," <i>J. of Lipid. Res.</i> , <b>1996</b> , <i>37</i> , 1334-1344	
	<b>6</b>	Chen, C.-S., et al., "Abnormal transport along the lysosomal pathway in mucolipidosis, type IV disease," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1998</b> , <i>95</i> , 6373-6378	
	<b>7</b>	Choo-Smith, L.-P., et al., "Acceleration of amyloidfibril formation by specific binding of A $\beta$ -(1-40) peptide to ganglioside-containing membrane vesicles," <i>J. of Biol. Chem.</i> , <b>1997</b> , <i>272</i> (37), 22987-22990	
	<b>8</b>	Cox, T., et al., "Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OBT 918) to decrease substrate biosynthesis," <i>The Lancet</i> , <b>2000</b> , <i>355</i> , 1481-1485	
	<b>9</b>	De Man, P., et al., "Bacterial adherence as a virulence factor in urinary tract infection," <i>APMIS</i> , <b>1990</b> , <i>98</i> , 1053-1060	
	<b>10</b>	Fowler, P.A., et al., "Synthesis and activity towards yeast $\alpha$ -glucosidase of 1,5-dideoxy-1,5-imino-L-iditol (1-deoxy-L-idonojirimycin)," <i>Carbohydr. Res.</i> , <b>1993</b> , <i>246</i> , 377-381	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>		Docket No. ACTE-0002	Application No. 10/522,208
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mezher Hussein Ali, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date October 27, 2005	Group 1615
		Confirmation No. 3691	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>11</b>	Geisler, F.H., "Clinical trials of pharmacotherapy for spinal cord injury," <i>Ann. NY Acad. Sci.</i> , <b>1998</b> , 845, 374-381	
	<b>12</b>	Goodman, L.A., et al., "Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in $\alpha$ -mannosidosis," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1991</b> , 88, 11330-11334	
	<b>13</b>	Handa, K., et al., "Analysis of glycolipid-dependent cell adhesion based on carbohydrate-carbohydrate interaction," <i>Methods in Enzymol.</i> , <b>2000</b> , 312, 447-458	
	<b>14</b>	Hansson, G.C., et al., "A novel approach to the study of glycolipid receptors for viruses," <i>FEBS Lett.</i> , <b>1984</b> , 170(1), 15-18	
	<b>15</b>	Jaranowska, A., et al., "Platelet-activating factor production by human fetal microglia," <i>Mol. &amp; Chem. Neuropathol.</i> , <b>1995</b> , 24, 95-106	
	<b>16</b>	Jimenez-Lucho, V., et al., " <i>Cryptococcus neoformans</i> , <i>candida albicans</i> , and other fungi bind specifically to the glycosphingolipid lactosylceramide (Gal $\beta$ 1-4Glc $\beta$ 1-1Cer), a possible adhesion receptor for yeasts," <i>Infect. &amp; Immun.</i> , <b>1990</b> , 58(7), 2085-2090	
	<b>17</b>	Jeyakumar, M., et al., "Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with <i>N</i> -butyldeoxynojirimycin," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1999</b> , 96, 6388-6393	
	<b>18</b>	Lavie, Y., et al., "Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporine A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells," <i>J. of Biol. Chem.</i> , <b>1997</b> , 272(3), 1682-1687	
	<b>19</b>	Li, R., et al., "Cellular gangliosides promote growth factor-induced proliferation of fibroblasts," <i>J. of Biol. Chem.</i> , <b>2000</b> , 275(44), 34213-34223	
	<b>20</b>	Lingwood, C.A., et al., "Analysis of interactions between glycosphingolipids and microbial toxins," <i>Methods in Enzymol.</i> , <b>2000</b> , 312, 459-473	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>		Docket No. ACTE-0002	Application No. 10/522,208
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mezher Hussein Ali, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date October 27, 2005	Group 1615
		Confirmation No. 3691	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>21</b>	Liu, Y.-Y., et al., "Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance," <i>J. Biol. Chem.</i> , <b>2000</b> , 275(10), 7138-7143	
	<b>22</b>	Lucci, A., et al., "Glucosylceramide: a marker for multiple-drug resistant cancers," <i>Anticancer Res.</i> , <b>1998</b> , 18, 475-480	
	<b>23</b>	McKallip, R., et al., "Tumor gangliosides inhibit the tumor-specific immune response," <i>J. Immunol.</i> , <b>1999</b> , 163, 3718-3726	
	<b>24</b>	Memon, R.A., et al., "Regulation of glycosphingolipid metabolism in liver during the acute phase response," <i>J. of Biol. Chem.</i> , <b>1999</b> , 274(28), 19707-19713	
	<b>25</b>	Memon, R.A., et al., "Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin," <i>J. of Lipid. Res.</i> , <b>2001</b> , 42, 452-459	
	<b>26</b>	Merrer, Y.L., et al., "Synthesis of azasugars as potent inhibitors of glycosidases," <b>1997</b> , 5(3), 519-533	
	<b>27</b>	Nicholson, K.M., et al., "Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase," <i>Br. J. Cancer</i> , <b>1999</b> , 81(3), 423-430	
	<b>28</b>	Overkleeft, H.S., et al., "Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase," <i>J. of Biol. Chem.</i> , <b>1998</b> , 273(41), 26522-26527	
	<b>29</b>	Platt, F.M., et al., "N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing," <i>J. Biol. Chem.</i> , <b>1994</b> , 269(43), 27108-27114	
	<b>30</b>	Platt, F.M., et al., "Prevention of lysosomal storage in tay-sachs mice treated with N-butyldeoxynojirimycin," <i>Science</i> , <b>1997</b> , 276, 428-431	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. ACTE-0002	Application No. 10/522,208
	Applicant Mezher Hussein Ali, et al.	
	Filing Date October 27, 2005	Group 1615
	Confirmation No. 3691	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
31	Poitout, L., et al., "Synthesis of azasugars. Part 1 – Simerization of polyhydroxylated piperidines," <i>Tetrahedron Letts.</i> , <b>1996</b> , 37(10), 1609-1612	
32	Prokazova, N.V., et al., "Gangliosides and atherosclerosis," <i>Lipids</i> , <b>1994</b> , 29, 1-5	
33	Rao, V.S., et al., "Regioselective eliminations in reactions of carbohydrate derivatives with superoxide, or with borohydride in 2-propanol," <i>Can. J. Chem.</i> , <b>1981</b> , 59(2), 333-338	
34	Ryan, J.L., et al., "Changes in membrane gangliosides: differentiation of human and murine monocytic cells," <i>Yale J. of Biol. Med.</i> , <b>1985</b> , 58, 125-131	
35	Schneider, J.S., "GM1 ganglioside in the treatment of Parkinson's Disease," <i>Ann. NY Acad. Sci.</i> , <b>1998</b> , 845, 363-373	
36	Simons, K., et al., "Functional rafts in cell membranes," <i>Nature</i> , <b>1997</b> , 387, 569-572	
37	Svensson, M., et al., "Carbohydrate receptor depletion as an antimicrobial strategy for prevention of urinary tract infection," <i>J. of Infect. Dis.</i> , <b>2001</b> , 183(Suppl. 1), S70 – S73	
38	Yanagisawa, K., et al., "GM1 ganglioside-bound amyloid $\beta$ -protein (A $\beta$ ): a possible form of preamyloid in Alzheimer's disease," <i>Nat. Med.</i> , <b>1995</b> , 1(10), 1062-1066	
39	Yohe, H.C., et al., "Ganglioside alternations in stimulated murine macrophages," <i>Biochimica et Biophys. Acta</i> , <b>1985</b> , 818, 81-86	
40	Yohe, H.C., et al., "Ganglioside expression in macrophages from endotoxin responder and nonresponder mice," <i>J. of Immunol.</i> , <b>1986</b> , 137, 3921-3927	
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. ACTE-0002	Application No. 10/522,208
		Applicant Mezher Hussein Ali, et al.	
		Filing Date October 27, 2005	Group 1615
		Confirmation No. 3691	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>41</b>	Yohe, H.C., et al., "The presence of sialidase-sensitive sialosylgangliotetraosyl ceramide (G <sub>M1b</sub> in stimulated murine macrophages," <i>J. of Immunol.</i> , <b>1991</b> , <i>146</i> , 1900-1908	
	<b>42</b>	Zador, I.Z., et al., "A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus," <i>J. Clin. Invest.</i> , <b>1993</b> , <i>91</i> , 797-803	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>	Docket No. ACTE-0002	Application No. 10/522,208
<p><b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)</p> <p>U.S. Department of Commerce Patent and Trademark Office</p>	<p><b>Applicant</b> Mezher Hussein Ali, et al.</p>	
	Filing Date October 27, 2005	Group 1615
	Confirmation No. 3691	

## **U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	43	WO 02/055498 A1	07/18/02	PCT		
	44	0 536 402 A1	04/14/93	EP		
	45	0 698 012 B1	01/29/97	EP		

**EXAMINER**

**DATE CONSIDERED**